Targeted therapies left out of ASCO breast cancer guideline for now
This article was originally published in Scrip
Executive Summary
The American Society of Clinical Oncology (ASCO) released a new treatment guideline on 2 September for women with HER2-negative advanced or metastatic breast cancer that appears to be in line with how doctors already treat patients with later-stage disease and excludes the few available targeted therapies.